Phar­ma gi­ants back a leader in vir­tu­al clin­i­cal tri­als as Covid-19 blights sites

While tra­di­tion­al tri­al sites are un­der enor­mous pres­sure amid the Covid-19 pan­dem­ic, 3 phar­ma gi­ants con­tin­ue to back a leader in vir­tu­al clin­i­cal tri­als.

Los An­ge­les-based Sci­ence 37 closed a $40 mil­lion fund­ing round on Fri­day, with in­vest­ments from No­var­tis, Am­gen and Sanofi Ven­tures. Lux Cap­i­tal, Red­mile Group and PPD led the round, and LifeSci Ven­tures and Mubadala Ven­tures joined in for the first time.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN